{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T06:41:46Z","timestamp":1775198506520,"version":"3.50.1"},"reference-count":50,"publisher":"Pharmaceutical Society of Japan","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2022,8,1]]},"DOI":"10.1248\/bpb.b22-00370","type":"journal-article","created":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T22:12:50Z","timestamp":1659305570000},"page":"979-984","source":"Crossref","is-referenced-by-count":6,"title":["Prostacyclin Synthase as an Ambivalent Regulator of Inflammatory Reactions"],"prefix":"10.1248","volume":"45","author":[{"given":"Tsubasa","family":"Ochiai","sequence":"first","affiliation":[{"name":"Division of Health Chemistry, Department of Healthcare and Regulatory Sciences, School of Pharmacy, Showa University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiya","family":"Honsawa","sequence":"additional","affiliation":[{"name":"Division of Health Chemistry, Department of Healthcare and Regulatory Sciences, School of Pharmacy, Showa University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Division of Health Chemistry, Department of Healthcare and Regulatory Sciences, School of Pharmacy, Showa University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuntaro","family":"Hara","sequence":"additional","affiliation":[{"name":"Division of Health Chemistry, Department of Healthcare and Regulatory Sciences, School of Pharmacy, Showa University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Narumiya S. Prostanoid receptors: structure, function, and distribution. <i>Ann. N. Y. Acad. Sci.<\/i>, <b>744<\/b>, 126\u2013138 (1994).","DOI":"10.1111\/j.1749-6632.1994.tb52729.x"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. <i>Annu. Rev. Biochem.<\/i>, <b>69<\/b>, 145\u2013182 (2000).","DOI":"10.1146\/annurev.biochem.69.1.145"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Smith WL, Urade Y, Jakobsson PJ. Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis. <i>Chem. Rev.<\/i>, <b>111<\/b>, 5821\u20135865 (2011).","DOI":"10.1021\/cr2002992"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Hara S. Prostaglandin terminal synthases as novel therapeutic targets. <i>Proc. Jpn. Acad., Ser. B, Phys. Biol. Sci.<\/i>, <b>93<\/b>, 703\u2013723 (2017).","DOI":"10.2183\/pjab.93.044"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. <i>JAMA<\/i>, <b>286<\/b>, 954\u2013959 (2001).","DOI":"10.1001\/jama.286.8.954"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Hara S, Kudo I. COX-2 inhibitors and the risk of cardiovascular events. <i>Jpn. Med. Assoc. J.<\/i>, <b>49<\/b>, 276\u2013278 (2006).","DOI":"10.5124\/jkma.2006.49.2.181"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Murakami M, Naraba H, Tanioka T, Semmyo N, Nakatani Y, Kojima F, Ikeda T, Fueki M, Ueno A, Oh-ishi S, Kudo I. Regulation of prostaglandin E<sub>2<\/sub> biosynthesis by inducible membrane-associated prostaglandin E<sub>2<\/sub> synthase that acts in concert with cyclooxygenase-2. <i>J. Biol. Chem.<\/i>, <b>275<\/b>, 32783\u201332792 (2000).","DOI":"10.1074\/jbc.M003505200"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Ueno N, Murakami M, Tanioka T, Fujimori K, Tanabe T, Urade Y, Kudo I. Coupling between cyclooxygenase, terminal prostanoid synthase, and phospholipase A<sub>2<\/sub>. <i>J. Biol. Chem.<\/i>, <b>276<\/b>, 34918\u201334927 (2001).","DOI":"10.1074\/jbc.M100429200"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Jakobsson PJ, Thor\u00e9n S, Morgenstern R, Samuelsson B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i>, <b>96<\/b>, 7220\u20137225 (1999).","DOI":"10.1073\/pnas.96.13.7220"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Stichtenoth DO, Thor\u00e9n S, Bian H, Peters-Golden M, Jakobsson PJ, Crofford LJ. Microsomal prostaglandin E synthase is regulated by proinflammatory cytokines and glucocorticoids in primary rheumatoid synovial cells. <i>J. Immunol.<\/i>, <b>167<\/b>, 469\u2013474 (2001).","DOI":"10.4049\/jimmunol.167.1.469"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Mancini JA, Blood K, Guay J, Gordon R, Claveau D, Chan CC, Riendeau D. Cloning, expression, and up-regulation of inducible rat prostaglandin E synthase during lipopolysaccharide-induced pyresis and adjuvant-induced arthritis. <i>J. Biol. Chem.<\/i>, <b>276<\/b>, 4469\u20134475 (2001).","DOI":"10.1074\/jbc.M006865200"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Trebino CE, Stock JL, Gibbons CP, Naiman BM, Wachtmann TS, Umland JP, Pandher K, Lapointe JM, Saha S, Roach ML, Carter D, Thomas NA, Durtschi BA, McNeish JD, Hambor JE, Jakobsson PJ, Carty TJ, Perez JR, Audoly LP. Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i>, <b>100<\/b>, 9044\u20139049 (2003).","DOI":"10.1073\/pnas.1332766100"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Kamei D, Yamakawa K, Takegoshi Y, Mikami-Nakanishi M, Nakatani Y, Oh-ishi S, Yasui H, Azuma Y, Hirasawa N, Ohuchi K, Kawaguchi H, Ishikawa Y, Ishii T, Uematsu S, Akira S, Murakami M, Kudo I. Reduced pain hypersensitivity and inflammation in mice lacking microsomal prostaglandin E synthase-1. <i>J. Biol. Chem.<\/i>, <b>279<\/b>, 33684\u201333695 (2004).","DOI":"10.1074\/jbc.M400199200"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Engblom D, Saha S, Engstr\u00f6m L, Westman M, Audoly LP, Jakobsson PJ, Blomqvist A. Microsomal prostaglandin E synthase-1 is the central switch during immune-induced pyresis. <i>Nat. Neurosci.<\/i>, <b>6<\/b>, 1137\u20131138 (2003).","DOI":"10.1038\/nn1137"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Hara S, Kamei D, Sasaki Y, Tanemoto A, Nakatani Y, Murakami M. Prostaglandin E synthases: understanding their pathophysiological roles through mouse genetic models. <i>Biochimie<\/i>, <b>92<\/b>, 651\u2013659 (2010).","DOI":"10.1016\/j.biochi.2010.02.007"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Ikeda-Matsuo Y, Ota A, Fukada T, Uematsu S, Akira S, Sasaki Y. Microsomal prostaglandin E synthase-1 is a critical factor of stroke-reperfusion injury. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i>, <b>103<\/b>, 11790\u201311795 (2006).","DOI":"10.1073\/pnas.0604400103"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Kihara Y, Matsushita T, Kita Y, Uematsu S, Akira S, Kira J, Ishii S, Shimizu T. Targeted lipidomics reveals mPGES-1-PGE2 as a therapeutic target for multiple sclerosis. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i>, <b>106<\/b>, 21807\u201321812 (2009).","DOI":"10.1073\/pnas.0906891106"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Akitake Y, Nakatani Y, Kamei D, Hosokawa M, Akatsu H, Uematsu S, Akira S, Kudo I, Hara S, Takahashi M. Microsomal prostaglandin E synthase-1 is induced in Alzheimer\u2019s disease and its deletion mitigates Alzheimer\u2019s disease-like pathology in a mouse model. <i>J. Neurosci. Res.<\/i>, <b>91<\/b>, 909\u2013919 (2013).","DOI":"10.1002\/jnr.23217"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Xu D, Rowland SE, Clark P, Giroux A, C\u00f4t\u00e9 B, Guiral S, Salem M, Ducharme Y, Friesen RW, M\u00e9thot N, Mancini J, Audoly L, Riendeau D. MF63 [2-(6-chloro-1<i>H<\/i>-phenanthro[9,10-<i>d<\/i>]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation. <i>J. Pharmacol. Exp. Ther.<\/i>, <b>326<\/b>, 754\u2013763 (2008).","DOI":"10.1124\/jpet.108.138776"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Bergqvist F, Morgenstern R, Jakobsson PJ. A review on mPGES-1 inhibitors: From preclinical studies to clinical applications. <i>Prostaglandins Other Lipid Mediat.<\/i>, <b>147<\/b>, 106383 (2020).","DOI":"10.1016\/j.prostaglandins.2019.106383"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Kamei D, Murakami M, Nakatani Y, Ishikawa Y, Ishii T, Kudo I. Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis. <i>J. Biol. Chem.<\/i>, <b>278<\/b>, 19396\u201319405 (2003).","DOI":"10.1074\/jbc.M213290200"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Kamei D, Murakami M, Sasaki Y, Nakatani Y, Majima M, Ishikawa Y, Ishii T, Uematsu S, Akira S, Hara S, Kudo I. Microsomal prostaglandin E synthase-1 in both cancer cells and hosts contributes to tumour growth, invasion and metastasis. <i>Biochem. J.<\/i>, <b>425<\/b>, 361\u2013371 (2010).","DOI":"10.1042\/BJ20090045"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Sasaki Y, Kamei D, Ishikawa Y, Ishii T, Uematsu S, Akira S, Murakami M, Hara S. Microsomal prostaglandin E synthase-1 is involved in multiple steps of colon carcinogenesis. <i>Oncogene<\/i>, <b>31<\/b>, 2943\u20132952 (2012).","DOI":"10.1038\/onc.2011.472"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Nakanishi M, Montrose DC, Clark P, Nambiar PR, Belinsky GS, Claffey KP, Xu D, Rosenberg DW. Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis. <i>Cancer Res.<\/i>, <b>68<\/b>, 3251\u20133259 (2008).","DOI":"10.1158\/0008-5472.CAN-07-6100"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Nakanishi M, Menoret A, Tanaka T, Miyamoto S, Montrose DC, Vella AT, Rosenberg DW. Selective PGE<sub>2<\/sub> suppression inhibits colon carcinogenesis and modifies local mucosal immunity. <i>Cancer Prev. Res. <\/i>(Phila.), <b>4<\/b>, 1198\u20131208 (2011).","DOI":"10.1158\/1940-6207.CAPR-11-0188"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Sasaki Y, Kuwata H, Aida E, Ochiai T, Kamei D, Nakatani Y, Hara S. Gene deletion of microsomal prostaglandin E synthase-1 suppresses chemically induced skin carcinogenesis. <i>Anticancer Res.<\/i>, <b>41<\/b>, 1307\u20131314 (2021).","DOI":"10.21873\/anticanres.14888"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Hara S, Miyata A, Yokoyama C, Inoue H, Brugger R, Lottspeich F, Ullrich V, Tanabe T. Isolation and molecular cloning of prostacyclin synthase from bovine endothelial cells. <i>J. Biol. Chem.<\/i>, <b>269<\/b>, 19897\u201319903 (1994).","DOI":"10.1016\/S0021-9258(17)32104-X"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Miyata A, Hara S, Yokoyama C, Inoue H, Ullrich V, Tanabe T. Molecular cloning and expression of human prostacyclin synthase. <i>Biochem. Biophys. Res. Commun.<\/i>, <b>200<\/b>, 1728\u20131734 (1994).","DOI":"10.1006\/bbrc.1994.1652"},{"key":"29","unstructured":"29) Tone Y, Inoue H, Hara S, Yokoyama C, Hatae T, Oida H, Narumiya S, Shigemoto R, Yukawa S, Tanabe T. The regional distribution and cellular localization of mRNA encoding rat prostacyclin synthase. <i>Eur. J. Cell Biol.<\/i>, <b>72<\/b>, 268\u2013277 (1997)."},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Hara S, Morishita R, Tone Y, Yokoyama C, Inoue H, Kaneda Y, Ogihara T, Tanabe T. Overexpression of prostacyclin synthase inhibits growth of vascular smooth muscle cells. <i>Biochem. Biophys. Res. Commun.<\/i>, <b>216<\/b>, 862\u2013867 (1995).","DOI":"10.1006\/bbrc.1995.2701"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Yokoyama C, Yabuki T, Shimonishi M, Wada M, Hatae T, Ohkawara S, Takeda J, Kinoshita T, Okabe M, Tanabe T. Prostacyclin-deficient mice develop ischemic renal disorders, including nephrosclerosis and renal infarction. <i>Circulation<\/i>, <b>106<\/b>, 2397\u20132403 (2002).","DOI":"10.1161\/01.CIR.0000034733.93020.BC"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Kuwamoto S, Inoue H, Tone Y, Izumi Y, Tanabe T. Inverse gene expression of prostacyclin and thromboxane synthases in resident and activated peritoneal macrophages. <i>FEBS Lett.<\/i>, <b>409<\/b>, 242\u2013246 (1997).","DOI":"10.1016\/S0014-5793(97)00516-4"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Sasaki Y, Kamiyama S, Kamiyama A, Matsumoto K, Akatsu M, Nakatani Y, Kuwata H, Ishikawa Y, Ishii T, Yokoyama C, Hara S. Genetic-deletion of cyclooxygenase-2 downstream prostacyclin synthase suppresses inflammatory reactions but facilitates carcinogenesis, unlike deletion of microsomal prostaglandin E synthase-1. <i>Sci. Rep.<\/i>, <b>5<\/b>, 17376 (2015).","DOI":"10.1038\/srep17376"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Murata T, Ushikubi F, Matsuoka T, Hirata M, Yamasaki A, Sugimoto Y, Ichikawa A, Aze Y, Tanaka T, Yoshida N, Ueno A, Oh-ishi S, Narumiya S. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. <i>Nature<\/i>, <b>388<\/b>, 678\u2013682 (1997).","DOI":"10.1038\/41780"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Ipseiz N, Pickering RJ, Rosas M, Tyrrell VJ, Davies LC, Orr SJ, Czubala MA, Fathalla D, Robertson AA, Bryant CE, O\u2019Donnell V, Taylor PR. Tissue-resident macrophages actively suppress IL-1\u03b2 release <i>via<\/i> a reactive prostanoid\/IL-10 pathway. <i>EMBO J.<\/i>, <b>39<\/b>, e103454 (2020).","DOI":"10.15252\/embj.2019103454"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Pan XY, Wang L, You HM, Cheng M, Yang Y, Huang C, Li J. Alternative activation of macrophages by prostacyclin synthase ameliorates alcohol induced liver injury. <i>Lab. Invest.<\/i>, <b>101<\/b>, 1210\u20131224 (2021).","DOI":"10.1038\/s41374-021-00531-7"},{"key":"37","unstructured":"37) Keith RL, Miller YE, Hoshikawa Y, Moore MD, Gesell TL, Gao B, Malkinson AM, Golpon HA, Nemenoff RA, Geraci MW. Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer. <i>Cancer Res.<\/i>, <b>62<\/b>, 734\u2013740 (2002)."},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Keith RL, Miller YE, Hudish TM, Girod CE, Sotto-Santiago S, Franklin WA, Nemenoff RA, March TH, Nana-Sinkam SP, Geraci MW. Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice. <i>Cancer Res.<\/i>, <b>64<\/b>, 5897\u20135904 (2004).","DOI":"10.1158\/0008-5472.CAN-04-1070"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Sasaki Y, Ochiai T, Takamura M, Kondo Y, Yokoyama C, Hara S. Role of prostacyclin synthase in carcinogenesis. <i>Prostaglandins Other Lipid Mediat.<\/i>, <b>133<\/b>, 49\u201352 (2017).","DOI":"10.1016\/j.prostaglandins.2017.05.001"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Honda T, Segi-Nishida E, Miyachi Y, Narumiya S. Prostacyclin-IP signaling and prostaglandin E<sub>2<\/sub>-EP2\/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis. <i>J. Exp. Med.<\/i>, <b>203<\/b>, 325\u2013335 (2006).","DOI":"10.1084\/jem.20051310"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Ochiai T, Sasaki Y, Kuwata H, Nakatani Y, Yokoyama C, Hara S. Coordinated action of microsomal prostaglandin E synthase-1 and prostacyclin synthase on contact hypersensitivity. <i>Biochem. Biophys. Res. Commun.<\/i>, <b>546<\/b>, 124\u2013129 (2021).","DOI":"10.1016\/j.bbrc.2021.02.004"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Yao C, Sakata D, Esaki Y, Li Y, Matsuoka T, Kuroiwa K, Sugimoto Y, Narumiya S. Prostaglandin E<sub>2<\/sub>-EP4 signaling promotes immune inflammation through T<sub>H<\/sub>1 cell differentiation and T<sub>H<\/sub>17 cell expansion. <i>Nat. Med.<\/i>, <b>15<\/b>, 633\u2013640 (2009).","DOI":"10.1038\/nm.1968"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Robb CT, McSorley HJ, Lee J, Aoki T, Yu C, Crittenden S, Astier A, Felton JM, Parkinson N, Ayele A, Breyer RM, Anderton SM, Narumiya S, Rossi AG, Howie SE, Guttman-Yassky E, Weller RB, Yao C. Prostaglandin E<sub>2<\/sub> stimulates adaptive IL-22 production and promotes allergic contact dermatitis. <i>J. Allergy Clin. Immunol.<\/i>, <b>141<\/b>, 152\u2013162 (2018).","DOI":"10.1016\/j.jaci.2017.04.045"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Nagamachi M, Sakata D, Kabashima K, Furuyashiki T, Murata T, Segi-Nishida E, Soontrapa K, Matsuoka T, Miyachi Y, Narumiya S. Facilitation of Th1-mediated immune response by prostaglandin E receptor EP1. <i>J. Exp. Med.<\/i>, <b>204<\/b>, 2865\u20132874 (2007).","DOI":"10.1084\/jem.20070773"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Nakajima S, Honda T, Sakata D, Egawa G, Tanizaki H, Otsuka A, Moniaga CS, Watanabe T, Miyachi Y, Narumiya S, Kabashima K. Prostaglandin I<sub>2<\/sub>-IP signaling promotes Th1 differentiation in a mouse model of contact hypersensitivity. <i>J. Immunol.<\/i>, <b>184<\/b>, 5595\u20135603 (2010).","DOI":"10.4049\/jimmunol.0903260"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Honda T, Matsuoka T, Ueta M, Kabashima K, Miyachi Y, Narumiya S. Prostaglandin E<sub>2<\/sub>-EP<sub>3<\/sub> signaling suppresses skin inflammation in murine contact hypersensitivity. <i>J. Allergy Clin. Immunol.<\/i>, <b>124<\/b>, 809\u2013818.e2 (2009).","DOI":"10.1016\/j.jaci.2009.04.029"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Ochiai T, Sasaki Y, Yokoyama C, Kuwata H, Hara S. Absence of prostacyclin greatly relieves cyclophosphamide-induced cystitis and bladder pain in mice. <i>FASEB J.<\/i>, <b>35<\/b>, e21952 (2021).","DOI":"10.1096\/fj.202101025R"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Dornelas-Filho AF, Pereira VBM, Wong DVT, Nobre LMS, Melo AT, Silva CMS, Wanderley CWS, Nour ML, Ara\u00fajo L, Silva RO, Pinto FMM, Bingana RD, Souza M, Alencar NMN, Silva PGB, Alves A, Almeida PRC, Cunha FQ, Lima-J\u00fanior RCP. Neutrophils contribute to the pathogenesis of hemorrhagic cystitis induced by ifosfamide. <i>Int. Immunopharmacol.<\/i>, <b>62<\/b>, 96\u2013108 (2018).","DOI":"10.1016\/j.intimp.2018.06.031"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Miki T, Matsunami M, Nakamura S, Okada H, Matsuya H, Kawabata A. ONO-8130, a selective prostanoid EP1 receptor antagonist, relieves bladder pain in mice with cyclophosphamide-induced cystitis. <i>Pain<\/i>, <b>152<\/b>, 1373\u20131381 (2011).","DOI":"10.1016\/j.pain.2011.02.019"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Bergqvist F, Carr AJ, Wheway K, Watkins B, Oppermann U, Jakobsson PJ, Dakin SG. Divergent roles of prostacyclin and PGE<sub>2<\/sub> in human tendinopathy. <i>Arthritis Res. Ther.<\/i>, <b>21<\/b>, 74 (2019).","DOI":"10.1186\/s13075-019-1855-5"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/45\/8\/45_b22-00370\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T03:33:25Z","timestamp":1659756805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/45\/8\/45_b22-00370\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,1]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b22-00370","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,1]]},"article-number":"b22-00370"}}